-
04:36:10 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

AXLA Stock News

08/02/22 6:00 AM
Nasdaq : AXLA
clinical trialcovid-19
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
Additionally, it was stated that Long COVID contributed to approximately $1 trillion in lost earnings and $529 billion in increased medical spending. Given the lack of therapeutic options for Long COVID patients and based on our understanding of AXA1125’ s positive impact on mitochondrial function, bioenergetics, and inflammation, Axcella conducted a...
RHEA-AI
neutral
05/26/22 7:00 AM
Nasdaq : AXLA
clinical trialcovid-19
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
Patient enrollment is complete in the prospective, placebo controlled, randomized trial conducted at the John Radcliffe Hospital at Oxford University in England. Betty Raman, British Heart Foundation Oxford Centre of Research Excellence Clinical Transition Intermediate Fellow, said,“ We have completed enrollment of the forty patients for this integral...
RHEA-AI
neutral
03/30/22 7:32 AM
Nasdaq : AXLA
earnings
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. This randomized, double-blind,...
RHEA-AI
very positive
03/16/22 8:15 AM
Nasdaq : AXLA
offering
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock at a...
RHEA-AI
neutral